MA32480B1 - Compositions pédiatriques pour le traitement de la sclérose en plaques - Google Patents

Compositions pédiatriques pour le traitement de la sclérose en plaques

Info

Publication number
MA32480B1
MA32480B1 MA33524A MA33524A MA32480B1 MA 32480 B1 MA32480 B1 MA 32480B1 MA 33524 A MA33524 A MA 33524A MA 33524 A MA33524 A MA 33524A MA 32480 B1 MA32480 B1 MA 32480B1
Authority
MA
Morocco
Prior art keywords
treatment
children
compositions
multiple sclerosis
sclerosis
Prior art date
Application number
MA33524A
Other languages
Arabic (ar)
English (en)
Inventor
Marie-Claude Bastien
John Kovarik
Robert Schmouder
Olivier David
Goeril Karlsson
Thomas Bouillon
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40974366&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32480(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA32480B1 publication Critical patent/MA32480B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques qui comportent un composé de 2-amino-2-[2-(4-c2-20-alkyl-phényl)éthyl]propane-1,3-diol ou un sel de qualité pharmaceutique de celui-ci, et l'utilisation de celui-ci pour traiter, prévenir ou retarder la progression d'une sclérose en plaques chez un patient pédiatrique ou un patient souffrant d'un état précis.
MA33524A 2008-06-20 2011-01-14 Compositions pédiatriques pour le traitement de la sclérose en plaques MA32480B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13262108P 2008-06-20 2008-06-20
PCT/US2009/047885 WO2009155475A1 (fr) 2008-06-20 2009-06-19 Compositions pédiatriques pour le traitement de la sclérose en plaques

Publications (1)

Publication Number Publication Date
MA32480B1 true MA32480B1 (fr) 2011-07-03

Family

ID=40974366

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33524A MA32480B1 (fr) 2008-06-20 2011-01-14 Compositions pédiatriques pour le traitement de la sclérose en plaques

Country Status (16)

Country Link
US (11) US20110152380A1 (fr)
EP (3) EP3011958A1 (fr)
JP (7) JP2011525189A (fr)
KR (4) KR20160131126A (fr)
CN (2) CN102076335A (fr)
BR (1) BRPI0914139A2 (fr)
CA (1) CA2728514C (fr)
CL (1) CL2010001463A1 (fr)
IL (2) IL209725A (fr)
MA (1) MA32480B1 (fr)
MX (1) MX2010014223A (fr)
NZ (1) NZ589618A (fr)
RU (1) RU2562571C2 (fr)
SG (1) SG10201406263SA (fr)
WO (1) WO2009155475A1 (fr)
ZA (1) ZA201008478B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011525189A (ja) 2008-06-20 2011-09-15 ノバルティス アーゲー 多発性硬化症を治療するための小児科の組成物
PT2356090T (pt) * 2008-11-11 2017-10-16 Novartis Ag Formas cristalinas de fingolimod, hcl
TW201028143A (en) * 2008-12-22 2010-08-01 Novartis Ag Dosage regimen for a S1P receptor agonist
NZ598534A (en) 2009-09-29 2014-03-28 Novartis Ag Dosage regimen of an s1p receptor modulator
JP6111202B2 (ja) 2011-01-07 2017-04-05 ノバルティス アーゲー 免疫抑制製剤
EP3027174B1 (fr) * 2013-07-29 2019-07-24 Aizant Drug Research Solutions Private Limited Compositions pharmaceutiques à base de fingolimod
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
DE69321823T2 (de) * 1992-10-21 1999-06-02 Taito Co., Ltd., Tokio/Tokyo 2-amino-1, 3- propandiolverbindung und immunosuppressium
SK78196A3 (en) 1993-12-17 1997-02-05 Sandoz Ag Rapamycin demethoxy-derivatives, preparation method thereof and pharmaceutical agent containing them
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5985890A (en) 1995-06-09 1999-11-16 Novartis Ag Rapamycin derivatives
AU735648B2 (en) 1996-07-12 2001-07-12 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
JP2002537293A (ja) 1999-02-20 2002-11-05 アストラゼネカ アクチボラグ カテプシンｌおよび／またはカテプシンｓの阻害剤としてのアセタミドアセトニトリル誘導体
EP1155011A1 (fr) 1999-02-20 2001-11-21 AstraZeneca AB Derives nitriles di- et tripeptidiques, utiles en tant qu'inhibiteurs des cathepsines l et s
GB9903861D0 (en) 1999-02-20 1999-04-14 Zeneca Ltd Chemical compounds
EP1159273A1 (fr) 1999-03-02 2001-12-05 Boehringer Ingelheim Pharmaceuticals Inc. Composes utiles en tant qu'inhibiteurs reversibles de la cathepsine s
GB9907683D0 (en) 1999-04-06 1999-05-26 Synphar Lab Inc Substituted azetidin-2-ones as cysteine protease inhibitors
EP1043027A1 (fr) * 1999-04-08 2000-10-11 Applied Research Systems ARS Holding N.V. Traitement combiné de l'esclerose multiple avec l'interferon et l'hormone de croissance
GB9911417D0 (en) 1999-05-18 1999-07-14 Peptide Therapeutics Ltd Furanone derivatives as inhibitors of cathepsin s
GB9917909D0 (en) 1999-07-31 1999-09-29 Synphar Lab Inc Cysteine protease inhibitors
ATE264863T1 (de) 1999-08-24 2004-05-15 Ariad Gene Therapeutics Inc 28-epirapaloge
EP1212302A1 (fr) 1999-09-16 2002-06-12 Axys Pharmaceuticals, Inc. Composes et compositions pharmaceutiques utilises comme inhibiteurs de la cathepsine s
GB9930449D0 (en) 1999-12-23 2000-02-16 Promotion & Display Tech Ltd Handset
CO5280088A1 (es) 2000-04-18 2003-05-30 Smithkline Beecham Corp Inhibidores de proteasa
HK1052705B (en) 2000-08-14 2006-09-29 Ortho-Mcneil Pharmaceutical, Inc. Substituted pyrazole
EP1309591B1 (fr) 2000-08-14 2007-01-24 Ortho-McNeil Pharmaceutical, Inc. Pyrazoles substitues
EP1309593B1 (fr) 2000-08-14 2006-03-15 Ortho-McNeil Pharmaceutical, Inc. Pyrazoles substitutes
EP1326848A1 (fr) 2000-10-19 2003-07-16 Naeja Pharmaceutical Inc. Derives de dihydropyrimidine utilises comme inhibiteurs de cysteine protease
MXPA03005601A (es) 2000-12-22 2004-12-02 Axys Pharm Inc Nuevos compuestos y composiciones como inhibidores de catepsina.
GB0121033D0 (en) 2001-08-30 2001-10-24 Novartis Ag Organic compounds
JP2005504078A (ja) 2001-09-14 2005-02-10 アベンティス・ファーマスーティカルズ・インコーポレイテツド カテプシン阻害剤としての新規化合物および組成物
US6900237B2 (en) 2001-09-14 2005-05-31 Axys Pharmaceuticals, Inc. Sulfonamide compounds as protease inhibitors
CA2459825A1 (fr) 2001-10-02 2003-04-10 Boehringer Ingelheim Pharmaceuticals, Inc. Composes utiles comme inhibiteurs reversibles de cysteine protease
CA2463770A1 (fr) 2001-10-29 2003-05-08 Boehringer Ingelheim Pharmaceuticals, Inc. Composes convenant comme inhibiteurs reversibles de proteases de la cysteine
WO2003041649A2 (fr) 2001-11-13 2003-05-22 Merck Frosst Canada & Co. Derives cyanoalkylamino utilises comme inhibiteurs de la protease
MXPA04004450A (es) 2001-11-14 2004-08-11 Aventis Pharma Inc Nuevos compuestos y composiciones como inhibidores de catepsina s.
EP1389480A1 (fr) * 2002-08-14 2004-02-18 Mondobiotech Interferon SA Utilisation thérapeutique de guanylhydrazones pour l'inhibition des procédés dépendant du CD83 et de la maturation des cellules dendritiques
EP1575576A2 (fr) * 2002-09-24 2005-09-21 Novartis AG Composes organiques
PE20130200A1 (es) 2003-04-08 2013-03-09 Novartis Ag Composicion farmaceutica que contiene un agonista del receptor s1p y un alcohol de azucar
WO2004094653A2 (fr) * 2003-04-22 2004-11-04 Irm Llc Analyse differentielle de la longueur des marqueurs de la proliferation cellulaire
AU2004271804B2 (en) * 2003-09-12 2011-01-06 Newron Sweden Ab Treatment of disorders of the nervous system
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas
US20090074720A1 (en) * 2005-10-28 2009-03-19 Sabbadini Roger A Methods for decreasing immune response and treating immune conditions
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
HUE046441T2 (hu) 2006-09-26 2020-02-28 Novartis Ag S1P modulátort tartalmazó gyógyászati készítmények
JP2011525189A (ja) 2008-06-20 2011-09-15 ノバルティス アーゲー 多発性硬化症を治療するための小児科の組成物

Also Published As

Publication number Publication date
AU2009259950A1 (en) 2009-12-23
CL2010001463A1 (es) 2011-05-06
IL209725A0 (en) 2011-02-28
JP2015107984A (ja) 2015-06-11
IL248919B (en) 2018-12-31
US20200197334A1 (en) 2020-06-25
JP2021152016A (ja) 2021-09-30
JP2017122106A (ja) 2017-07-13
US20130230489A1 (en) 2013-09-05
SG10201406263SA (en) 2015-02-27
WO2009155475A1 (fr) 2009-12-23
RU2562571C2 (ru) 2015-09-10
ZA201008478B (en) 2012-01-25
US20190358178A1 (en) 2019-11-28
BRPI0914139A2 (pt) 2015-10-20
NZ589618A (en) 2012-09-28
JP2018184424A (ja) 2018-11-22
KR20180017232A (ko) 2018-02-20
CN102076335A (zh) 2011-05-25
CA2728514A1 (fr) 2009-12-23
MX2010014223A (es) 2011-01-21
CA2728514C (fr) 2020-08-11
KR20160131126A (ko) 2016-11-15
EP2303250A1 (fr) 2011-04-06
US20170128389A1 (en) 2017-05-11
KR20110020928A (ko) 2011-03-03
US20190117593A1 (en) 2019-04-25
US20170333368A1 (en) 2017-11-23
US20110152380A1 (en) 2011-06-23
IL209725A (en) 2016-11-30
RU2011101771A (ru) 2012-07-27
US20160022611A1 (en) 2016-01-28
IL248919A0 (en) 2017-01-31
JP2020063269A (ja) 2020-04-23
KR20170081755A (ko) 2017-07-12
JP2011525189A (ja) 2011-09-15
JP2023153786A (ja) 2023-10-18
US20160206574A1 (en) 2016-07-21
US20210023027A1 (en) 2021-01-28
CN104800196A (zh) 2015-07-29
EP3545953A1 (fr) 2019-10-02
EP3011958A1 (fr) 2016-04-27
US20180177747A1 (en) 2018-06-28

Similar Documents

Publication Publication Date Title
MA32480B1 (fr) Compositions pédiatriques pour le traitement de la sclérose en plaques
UA113165C2 (xx) Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
WO2010055028A3 (fr) Composés organiques
EP2249861A4 (fr) Traitement de maladies neurodégénératives avec de la progranuline (pgrn)
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
WO2010115041A3 (fr) Compositions orales utilisables dans le cadre du traitement de la sensibilité dentaire et leurs procédés d'utilisation et de fabrication
CY1112320T1 (el) Τιτλοδοτηση της ταπενταδολης
UA109650C2 (xx) Біс-арилзв'язані арилтриазолони та їх застосування
EA201170465A1 (ru) Способы лечения прогрессирующего множественного склероза
CN102036649A8 (zh) 精氨酸盐及其治疗口腔疾病的用途
SI1824563T1 (sl) Sestavki, ki obsegajo ornitin in fenilacetat ali fenilbutirat, za zdravljenje hepatične encefalopatije
HK1199820A1 (en) Treatment of multiple sclerosis with combination of laquinimod and fingolimod
BR112014015568A2 (pt) compostos carbamato de fenila para uso em prevenção ou tratamento de epilepsia
WO2010036395A3 (fr) Traitement de l’exposition aux organophosphates au moyen de composés de tétrahydroindolone arylpipérazine
MY153948A (en) Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
WO2011159840A3 (fr) Phénylthioacétates, compositions et procédés d'application
EA201600442A1 (ru) Мягкая фармацевтическая композиция на водной основе, содержащая тапентадол
ZA201101278B (en) Compounds,compositions and methods for the treatment of b-amyloid diseases and synucleinopathies
WO2013098416A3 (fr) Composes anti-douleur
MY143269A (en) Use of agomelatine in obtaining medicaments intended for the treatment of generalized anxiety disorder
EP2667885A4 (fr) Compositions et procédés pour apporter ou moduler le goût sucré, et procédés de recherche systématique s'y rapportant
CL2013001482A1 (es) Compuestos derivados de 3-metil-7-oxo-4-tia-1-aza-biciclo[3.2.0]heptano para utilizarse en la inhibicion de beta-lactamasas producidas por bacterias y restaurar/potenciar la actividad de antibioticos; y composicion farmaceutica que los comprende.
BR112012007888A2 (pt) "métodos de tratamento usando anticorpos anti-ldl oxidada".
EA201170267A1 (ru) Способ лечения гиперчувствительности зубов
AU2016216741A1 (en) Compositions and methods of use of an inappetance-controlling compound